SEC Company Response from Quoin Pharmaceuticals (QNRX) — Dec 2, 2025
Quoin Pharmaceuticals Ltd.
Date: Dec. 2, 2025 · CIK: 0001671502 · Accession: 0001104659-25-117689
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291385
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Dan Crawford Re: Quoin Pharmaceuticals, Ltd. Registration Statement on Form S-3 Filed November 7, 2025 File No: 333-291385
Dear Mr. Crawford:
Quoin Pharmaceuticals, Ltd. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-291385) (the "Registration Statement ") be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Thursday, December 4, 2025 , at 5:00 p.m ., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify Ms. Murawsky when this request for acceleration has been granted.
Very truly yours,
QUOIN PHARMACEUTICALS, LTD.
Show Raw Text
CORRESP 1 filename1.htm December 2, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dan Crawford Re: Quoin Pharmaceuticals, Ltd. Registration Statement on Form S-3 Filed November 7, 2025 File No: 333-291385 Dear Mr. Crawford: Quoin Pharmaceuticals, Ltd. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-291385) (the "Registration Statement ") be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Thursday, December 4, 2025 , at 5:00 p.m ., Eastern Time, or as soon as reasonably practicable thereafter. The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. The Registrant hereby authorizes Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify Ms. Murawsky when this request for acceleration has been granted. Very truly yours, QUOIN PHARMACEUTICALS, LTD. By: /s/ Michael Myers Name: Dr. Michael Myers Title: Chief Executive Officer cc: Melissa Palat Murawsky, Esq., Blank Rome LLP